Literature DB >> 11166091

Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report.

M P Austin1, P Mitchell, D Hadzi-Pavlovic, I Hickie, G Parker, J Chan, K Eyers.   

Abstract

Given the many clinical parallels between melancholia and disorders associated with impaired dopaminergic function such as Parkinson's Disease (PD), it has been hypothesised that major depressive disorder, and in particular the psychomotor features of melancholic depression, may also be associated with a hypodopaminergic state. If this is the case, then the use of a dopamine agonist might lead to reversal of both the cognitive and motor impairments seen in these patients. A double-blind, placebo-controlled cross-over design was used to test the effect of apomorphine on motor and cognitive function in seven melancholic subjects (as defined by the CORE instrument) and five control subjects. The testing battery included the following items: finger tapping, rapid alternating movements, verbal fluency, Rey Auditory Verbal Learning Task, digit symbol substitution task and simple and complex reaction times. The independent t-test, after covarying for age, revealed significant impairment in melancholic subjects for the walking task and digit symbol substitution at baseline. Results of the ANCOVA revealed no impact of time or drug condition, either alone or in combination, upon task performance in either group whether assessed separately or jointly. Results of a MANCOVA revealed that apomorphine impaired performance on some cognitive tasks, and that this was seen to a lesser extent in melancholics than control subjects. There was no evidence that the dopamine agonist apomorphine improved cognitive or motor function in subjects with strictly defined melancholia, suggesting that psychomotor retardation is not associated with a hypodopaminergic state. Our conclusions, however, were limited by small sample size; minimal baseline task impairment in depressed compared to control subjects; mild sedation in many subjects during task performance; and lack of serum apomorphine levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11166091     DOI: 10.1016/s0165-1781(00)00222-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

Review 1.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

Review 2.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 3.  Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications.

Authors:  Djamila Bennabi; Pierre Vandel; Charalambos Papaxanthis; Thierry Pozzo; Emmanuel Haffen
Journal:  Biomed Res Int       Date:  2013-10-30       Impact factor: 3.411

4.  Functional and structural alterations in the cingulate motor area relate to decreased fronto-striatal coupling in major depressive disorder with psychomotor disturbances.

Authors:  Benny Liberg; Paul Klauser; Ian H Harding; Mats Adler; Christoffer Rahm; Johan Lundberg; Thomas Masterman; Caroline Wachtler; Tomas Jonsson; Maria Kristoffersen-Wiberg; Christos Pantelis; Björn Wahlund
Journal:  Front Psychiatry       Date:  2014-12-04       Impact factor: 4.157

Review 5.  Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.

Authors:  Flavie Darcet; Alain M Gardier; Raphael Gaillard; Denis J David; Jean-Philippe Guilloux
Journal:  Pharmaceuticals (Basel)       Date:  2016-02-17

6.  Regional cerebral metabolism alterations affect resting-state functional connectivity in major depressive disorder.

Authors:  Hui Su; Chuantao Zuo; Huiwei Zhang; Fangyang Jiao; Bin Zhang; Weijun Tang; Daoyin Geng; Yihui Guan; Shenxun Shi
Journal:  Quant Imaging Med Surg       Date:  2018-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.